NASDAQ$CTMX
CytomX Therapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close
Briefing
CytomX reported FY 2025 revenue of $76.2M and ended the year with $137.1M in cash.
Full-year revenue was $76.2 million versus $138.1 million in 2024, primarily due to completion of Bristol Myers Squibb performance obligations and lower collaboration revenue recognition. Operating expenses fell $14.5 million to $98.6 million. Cash was $137.1 million with runway into Q2 2027.
- Cash runway extended to Q2 2027 on reduced burn.
- CX-801 combination with KEYTRUDA dose escalation ongoing.
- January 2025 restructuring lowered R&D spend.
- Collaboration revenue recognition slowed vs prior year.
- Focused pipeline on masked conditionally activated biologics.
Headline financials
Revenue & EPS history
CytomX Therapeutics Inc · Revenue · Quarterly
$76.2M
Forward guidance
No quantitative revenue guidance; runway supports operations into Q2 2027.
Tailwinds
- Lower operating expenses after restructuring.
- Multiple early-stage oncology programs advancing.
Headwinds
- Revenue decline from completed BMS obligations.
- Clinical-stage biotech with ongoing burn.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+3.6%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.5%
Avg return
30 days after
53%
16 / 30 earnings
Positive
+129.5%
Q1 2025
Best reaction
-19.3%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.4% | -6.3% | -27.8% | |
| Q4 2025 | -19.3% | -34.1% | -27.6% | |
| Q3 2025 | -0.5% | -2.6% | -6.2% | |
| Q1 2025 | +129.5% | +118.8% | +203.9% | |
| Q3 2024 | +0.0% | +4.0% | +18.0% | |
| Q2 2024 | +1.7% | +0.0% | +3.4% | |
| Q1 2024 | +2.9% | -53.6% | -59.7% | |
| Q3 2023 | +0.8% | -7.9% | +15.0% | |
| Q2 2023 | -0.6% | -1.2% | -18.8% | |
| Q1 2023 | +2.4% | +6.0% | +3.6% | |
| Q3 2022 | -1.6% | +3.2% | +29.6% | |
| Q2 2022 | +3.8% | +1.9% | -7.0% | |
| Q1 2022 | -5.8% | +4.1% | +4.1% | |
| Q3 2021 | -2.0% | +14.8% | +8.4% | |
| Q2 2021 | +3.8% | -12.0% | -7.9% | |
| Q1 2021 | -4.5% | -4.5% | -20.6% | |
| Q3 2020 | +0.0% | +5.7% | +4.7% | |
| Q2 2020 | +1.3% | -6.2% | -11.9% | |
| Q1 2020 | +1.7% | +21.5% | -33.1% | |
| Q3 2019 | +0.8% | -9.8% | +3.1% | |
| Q2 2019 | +2.6% | -7.3% | -19.9% | |
| Q1 2019 | -0.1% | +7.2% | +3.4% | |
| Q3 2018 | -8.8% | +7.3% | -1.1% | |
| Q2 2018 | +1.6% | -4.2% | -19.4% | |
| Q1 2018 | +0.9% | -3.6% | +2.2% | |
| Q3 2017 | -1.7% | -1.4% | +0.4% | |
| Q2 2017 | +0.2% | +2.6% | +23.1% | |
| Q1 2017 | +2.3% | -0.2% | -2.3% | |
| Q3 2016 | -2.8% | -5.7% | -2.3% | |
| Q2 2016 | +3.2% | +10.8% | +19.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro